Actiza Pharmaceutical Private Limited

Venetoclax is a selective and orally bioavailable small - molecule inhibitor of BCL-2 , an anti-apoptotic protein . Overexpression of BCL-2 has been demonstrated in CLL cells , where it mediates tumor cell survival and is concomitantly resistant to chemotherapy. Venetoclax helps restore the apoptotic process by binding directly to the BCL-2 protein, displacing pro-apoptotic proteins like BIM , triggering mitochondrial outer membrane permeabilization and activation of cysteine proteases [caspases] . In non-clinical studies, venetoclax has been Displays cytotoxic activity against tumor cells overexpressing BCL-2 .

Indications

Suitable for chromosome 17p deletion or relapsed / refractory chronic lymphocytic leukemia ( CLL ).

Specification   

100mg/ tablet, 120 tablets / box.

• Mephentermine Sulphate 30mg Injection is used to raise blood pressure in hypotensive (low blood pressure) states, such as following spinal anesthesia. It increases the blood pressure rapidly by increasing the pumping capacity of the heart and narrowing blood vessels of the heart.
• Mephentermine Sulphate 30mg Injection is administered under the supervision of a doctor. Your doctor will decide the dose and duration of the medicine for you. You should continue all your other medicines that are advised by the doctor for your long-term treatment even after this injection. Your doctor may advise for regular monitoring of blood pressure while your taking this medicine.

Cabozantinib was developed by the American Exelixis biopharmaceutical company. It is a multi-target broad-spectrum anti-cancer drug. The targets that can be inhibited include: MET , VEGFR1/2/3 , ROS1 , RET , AXL , NTRK , KIT and other at least 9 .

At present, cabozantinib has proven good therapeutic effects in a variety of solid tumors such as kidney cancer, thyroid cancer, liver cancer, soft tissue sarcoma, non-small cell lung cancer, prostate cancer, breast cancer, ovarian cancer, intestinal cancer, etc. The control effect on bone metastasis is particularly outstanding. Cabozantinib is known as the " Taiwan Balm " among targeted drugs because of its broad effectiveness against a variety of cancers . Targets include: KIT, PDGFR, FGFR, BRAF, BRAFV600, RAF-1, VEGFR1/2/3, TIE-1/-2, RET .

Indications

1. Treatment of progressive, unresectable locally advanced or metastatic medullary thyroid cancer;

2. Advanced renal cancer that fails Sutent treatment;

3. Patients with advanced non-small cell lung cancer with C-met amplification;

4. Liver cancer patients who are resistant to Nexavar;

5. Patients wi advanced prostate cancer who develop bone metastasis .